宋腾, 张亚瑞, 赵可, 李书苹, 常智, 柳凤亭, 王华庆. 预后营养指数评估弥漫性大B细胞淋巴瘤患者预后的临床价值[J]. 中国肿瘤临床, 2019, 46(17): 903-908. DOI: 10.3969/j.issn.1000-8179.2019.17.941
引用本文: 宋腾, 张亚瑞, 赵可, 李书苹, 常智, 柳凤亭, 王华庆. 预后营养指数评估弥漫性大B细胞淋巴瘤患者预后的临床价值[J]. 中国肿瘤临床, 2019, 46(17): 903-908. DOI: 10.3969/j.issn.1000-8179.2019.17.941
shu
Song Teng, Zhang Yarui, Zhao Ke, Li Shuping, Chang Zhi, Liu Fengting, Wang Huaqing. The prognostic value of prognostic nutritional index in patients with diffuse large B-cell lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(17): 903-908. DOI: 10.3969/j.issn.1000-8179.2019.17.941
Citation: Song Teng, Zhang Yarui, Zhao Ke, Li Shuping, Chang Zhi, Liu Fengting, Wang Huaqing. The prognostic value of prognostic nutritional index in patients with diffuse large B-cell lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(17): 903-908. DOI: 10.3969/j.issn.1000-8179.2019.17.941
shu

预后营养指数评估弥漫性大B细胞淋巴瘤患者预后的临床价值

The prognostic value of prognostic nutritional index in patients with diffuse large B-cell lymphoma

    摘要
  • 摘要:
      目的  探讨预后营养指数（prognostic nutritional index，PNI）与弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）患者临床特征及预后之间的关系。
      方法  回顾性收集2010年6月至2016年6月于天津市人民医院收治的82例初治DLBCL患者的临床资料，计算PNI值，采用受试者工作特征曲线（ROC）计算Youden指数，获取PNI最佳分界值，分析不同PNI水平与患者临床特征、治疗疗效及预后的关系。
      结果  全组患者PNI均值为43.93±5.86，当PNI值为44.15时，Youden指数最大，敏感度为74.6%，特异度为67.2%。低PNI组（< 44.15）和高PNI组（≥44.15）患者分别占38例（46.3%）和44例（53.7%），PNI水平与患者的ECOG PS评分、Ann Arbor分期、IPI评分、LDH水平等均有相关性（均P < 0.05）。低PNI组患者化疗总有效率低于高PNI组（65.8% vs.86.4%），且差异具有统计学意义（χ2=4.848，P=0.028）。全组患者3年生存率为69.1%，低PNI组1、2、3年生存率分别为86.8%、67.8%和56.9%，均低于高PNI组96.7%、89.5%和80.2%，差异具有统计学意义（χ2=9.421，P=0.002）。单因素分析显示患者PNI值< 44.15、ECOG PS评分≥2分、IPI评分>2分、分期Ⅲ~Ⅳ期、外周血淋巴细胞计数 < 1.0×109/L对预后有影响（均P < 0.05），多因素分析显示PNI值< 44.15和Ⅲ/Ⅳ期为影响该组患者的独立预后不良因素（P=0.006，0.011）。
      结论  PNI值可作为DLBCL患者简便可行的临床预后指标。

     

    Abstract:
      Objective  To investigate the prognostic value of prognostic nutritional index (PNI) in patients with diffuse large B-cell lymphoma (DLBCL).
      Methods  We retrospectively reviewed the medical records of 82 patients with DLBCL treated at Tianjin Union Medical Center between June 2010 and June 2016. The optimal cutoff value of PNI was determined using a receiver operating characteristic (ROC) curve and the Youden index. The relationship of high and low PNI with the clinical characteristics of the patients, therapeutic efficacy, and prognosis were analyzed.
      Results  Overall, mean PNI of the patients was 46.17±8.8. When the PNI was 44.15, the Youden index was found to be maximal, with a sensitivity of 74.6% and specificity of 67.2%. There were 38 patients (46.3%) in the low PNI group (< 44.15) and 44 patients (53.7%) in the high PNI group (≥ 44.15). Data analysis showed that PNI was correlated with Eastern Cooperative Oncology Group performance status (ECOG PS), Ann Arbor stage, international prognostic index (IPI) score, and lactic acid dehydrogenase (LDH) level (P < 0.05). The total effective rate of the low PNI group was significantly lower than that of the high PNI group (65.8% vs. 86.4%; χ2=4.848; P=0.028). The 3-year overall survival (OS) rate of the entire group of patients was 69.1%. The 1-, 2-, and 3-year OS rates of the low PNI group (86.8%, 67.8%, and 56.9%, respectively) were significantly lower than that of the high PNI group (96.7%, 89.5%, and 80.2%, respectively; χ2=9.421, P=0.002). Univariate analysis showed that PNI < 44.15, ECOG PS ≥ 2, IPI>2, stage Ⅲ/Ⅳ, and lymphocyte count < 1.0×109/L had a significant impact on predicting OS (P < 0.05). Multivariate analysis showed that PNI < 44.15 (P=0.006) and stage Ⅲ/Ⅳ (P=0.011) were independent factors for predicting OS.
      Conclusions  PNI might be used as a simple and feasible clinical prognostic indicator in patients with DLBCL.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回